Gene Therapy Market by Vector Type (Viral Vector and Non-viral Vector), Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others), and Applications (Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases) - Global Opportunity Analysis and Industry Forecast, 2017-2023
The global gene therapy market was valued at $584 million in 2016, and is estimated to reach $4,402 million by 2023, registering a CAGR of 33.3% from 2017 to 2023. Gene therapy is a technique that involves the delivery of nucleic acid polymers into a patients cells as a drug to treat diseases.
It fixes a genetic problem at its source. The process involves modifying the protein either to change the genetic expression or to correct a mutation.
The emergence of this technology meets the rise in needs for better diagnostics and targeted therapy tools.
For instance, genetic engineering can be used to modify physical appearance, metabolism, physical capabilities, and mental abilities such as memory and intelligence. In addition, it is also used for infertility treatment.
Gene therapy offers a ray of hope for patients, who either have no treatment options or show no benefits with drugs currently available. The ongoing success has strongly supported upcoming researches and has carved ways for enhancement of gene therapy.
The gene therapy market is a widely expanding field in the pharmaceutical industry with new opportunities. This has piqued the interests of venture capitalists to explore this market and its commercial potential.
Major factors that drive the growth of this market include high demands for DNA vaccines to treat genetic diseases, targeted drug delivery, and high incidence of genetic disorders. However, the stringent regulatory approval process for gene therapy and the high costs of gene therapy drugs are expected to hinder the growth of the market.
The global gene therapy market is segmented based on vector type, gene type, application, and geography. Based on vector type, it is categorized into viral vector and non-viral vector.
Viral vector is further segmented into retroviruses, lentiviruses, adenoviruses, adeno associated virus, herpes simplex virus, poxvirus, vaccinia virus, and others. Non-viral vector is further categorized into naked/plasmid vectors, gene gun, electroporation, lipofection, and others.
Based on gene type, the market is classified into antigen, cytokine, tumor suppressor, suicide, deficiency, growth factors, receptors, and others.
Based on application, the market is divided into oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious disease, and other diseases. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY MARKET BENEFITS This report offers a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities. The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry. In-depth analysis based on geography facilitates in analyzing the regional market to assist in strategic business planning. The development strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market.
By Gene Type Antigen Cytokine Tumor Suppressor Suicide Deficiency Growth factors Receptors Others
By Application Oncological Disorders Rare Diseases Cardiovascular Diseases Neurological Disorders Infectious disease Other Diseases
By Region North America U.S. Canada Mexico Europe Germany UK France Spain Italy Rest of Europe Asia-Pacific Japan China India South Korea Rest of Asia-Pacific LAMEA Brazil Republic of South Africa Rest of LAMEA
KEY PLAYERS PROFILED Novartis Kite Pharma, Inc. GlaxoSmithKline PLC Spark Therapeutics Inc. Bluebird bio Inc. Genethon Transgene SA Applied Genetic Technologies Corporation Oxford BioMedica NewLink Genetics Corp.
The other players of the gene therapy market include (companies not profiled in the report): Amgen Epeius Biotechnologies Abeona Therapeutics Sanofi UniQure Juno Therapeutics Adaptimmune Celgene Advantagene
Our reports have been used by over 10K customers, including:
INTRODUCTION Over the years, advances in cell biology and pharmacology have led to the development of a variety of advanced biologics, which experts believe, possess the potential to address several unmet needs associated with the treatment of different types of diseases. Currently, there are more than 1,000 cell and gene...
200 pages •
By The Business Research Company
• Jul 2020
Major players in the viral vectors & plasmid DNA market are FUJIFILM Diosynth Biotechnologies, FinVector Vision Therapies, Lonza, Cobra Biologics and Pharmaceutical Services, Brammer Bio, ??n?k? ??r??r?t??n, Cell and Gene Therapy Catapult, VGXI, and MassBiologics. The global viral vectors & plasmid DNA market is expected to grow from...
Viral Vector & Plasmid DNA Manufacturing Market Research Report by Type (Adeno-Associated Virus, Adenovirus, Lentivirus, and Plasmid DNA), by Indication (Cancer, Genetic Disorder, and Infectious Disease), by Application, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19 The Global Viral Vector &...
129 pages •
By Global Industry Analysts
• Sep 2020
Global Cancer Gene Therapy Market to Reach $3.8 Billion by 2027 Amid the COVID-19 crisis, the global market for Cancer Gene Therapy estimated at US$611.9 Million in the year 2020, is projected to reach a revised size of US$3.8 Billion by 2027, growing at a CAGR of 29.6% over the analysis period 2020-2027. Oncolytic Virotherapy, one...
Gene Therapy Market Research Report by Type (Antigen Gene Therapy, Cancer Gene Therapy, Cytokine Gene Therapy, Suicide Gene Therapy, and Tumor Suppressor Gene Therapy), by Vector Type (Non-viral Vectors and Viral Vectors), by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19 The Global Gene Therapy...
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Cell and Gene Therapy Market Report The global cell and gene therapy market by revenue is expected to grow at a CAGR of over 30.90% during the period 2019–2025. The global cell and gene therapy market is one of the fastest-growing segments...
Lysosomal Alpha Glucosidase - Pipeline Review, H2 2020 Summary Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 184.108.40.206) - Lysosomal alpha-glucosidase is an enzyme encoded by the GAA gene. It is essential for the degradation of glygogen to glucose in lysosomes. Defects...
Wounds - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Wounds - Pipeline Review, H1 2020, provides an overview of the Wounds (Dermatology) pipeline landscape. Wound is a breakdown in the protective function of the skin (the loss of continuity...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.